Anti-Platelets in Chronic Obstructive Pulmonary Disease

Phase 2 Completed NCT05567562

Condition	COPD, Emphysema, Emphysema or COPD
Phase	Phase 2
Sponsor	Brigham and Women's Hospital
Status	Completed
Enrollment	15 participants
Interventions	dual anti-platelet therapy
Start date	Mar 27, 2024
Completion date	Feb 28, 2025
Results posted	May 14, 2026

Summary

This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.

Pulmonary Microvascular Blood Volume, CV

After 2 weeks of therapy · CV

On Dual Anti-platelet Therapy	0.89 ± 0.079 CV
On Placebo	0.88 ± 0.072 CV
On Dual Anti-platelet Therapy, COPD	0.92 ± 0.064 CV
On Placebo, COPD	0.91 ± 0.052 CV
On Dual Anti-platelet Therapy, Controls	0.81 ± 0.051 CV
On Placebo, Controls	0.80 ± 0.042 CV

p-value	0.84

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский